EBEmanuela M. Bruscia

Emanuela M. Bruscia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emanuela M. Bruscia has a total of 218 co-authors. Here are the top co-authors by number of shared publications:

  • Ping-Xia Zhang

    Department of Pediatrics, School of Medicine, Yale University, New Haven, USA

    9 shared publications
  • Diane S. Krause

    Yale Stem Cell Center, School of Medicine, Yale University, New Haven, USA

    8 shared publications
  • Caterina Di Pietro

    Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA

    7 shared publications
  • Thomas S. Murray

    Department of Pediatrics, School of Medicine, Yale University, New Haven, USA

    7 shared publications
  • Marie E. Egan

    Department of Pediatrics, School of Medicine, Yale University, New Haven, USA

    5 shared publications
  • Hasan H. Öz

    Departments of Pediatrics, Yale University School of Medicine

    4 shared publications

Latest Publications

  • Open Access

    An N,S -acetylated L-cysteine-cysteamine conjugate hinders pyocyanin redox cycling to weaken Pseudomonas aeruginosa biofilm and dampens LPS-driven acute pulmonary inflammation

    by Michela Bruschi, Sofia Masini, Francesco Palma, Yang Xiaoqiu, Cassia Lisboa Braga, Matteo Gregori, Cecilia Bucci, Francesca Bartoccini, Michele Menotta, Elisabetta Manuali, et al.

    The persistence of P. aeruginosa infections is largely driven by the secretion of several factors during invasion, including the redox-active phenazine pyocyanin (PYO), which promotes biofilm formation and oxidative stress. Biofilms contribute to chronic infections and antibiotic resistance, limiting the efficacy of conventional therapies. We found that a synthetic compound, I-152, a conjugate of N-acetyl-L-cysteine (NAC) and S-acetylcysteamine (also known as S-acetyl-β-mercaptoethylamine; SMEA), effectively restored colistin susceptibility against P. aeruginosa by altering biofilm nanomechanical properties. These perturbations in matrix integrity were associated with I-152’s ability to hinder the phenazine redox cycle, shifting PYO to a reduced state as well as enabling S-conjugate formation. The compound decreased PYO accumulation in bacterial cultures and PYO-generated reactive oxygen species (ROS) in macrophage cells. Together with PYO, LPS is another driver of ROS-dependent inflammatory signaling in the host, which leads to an uncontrolled cytokine response and organ damage, especially in patients with cystic fibrosis. I-152 treatment downregulated the expression of LPS-induced inflammatory cytokines, i.e., IL-6 and TNF-α, in bone marrow-derived macrophages (BMDM) isolated from transgenic CFTR -/- and CFTR +/+ mice. Consistently, I-152 partially counteracted the inflammatory response in the P. aeruginosa LPS-induced acute lung injury murine model. Taken together, these results support I-152 as an adjunctive treatment for P. aeruginosa respiratory infections through a dual mechanism: combating antimicrobial resistance in biofilms and dampening host inflammation in the respiratory system. Highlights: I-152 potentiates colistin activity against P. aeruginosa by compromising the biofilm surface I-152 rewires the pyocyanin (PYO) redox state and forms covalent adducts with it PYO accumulation and PYO-induced ROS generation in macrophages is impaired by I-152 Ex vivo, I-152 dampens excessive pro-inflammatory response to P. aeruginosa LPS in CFTR - / - and CFTR + / + BM-derived macrophages I-152 (140 mg/Kg) attenuates LPS-driven inflammation and lung damage in CFTR + / + mice

  • Open Access

    Increased prevalence of autoantibodies neutralizing IFNλ2/3 in young individuals with cystic fibrosis

    by Kevin Groen, Chau Tran, Roger Kuratli, Marie E. Egan, Johannes Trück, Emanuela M. Bruscia, Marc Emmenegger, Benjamin G. Hale

    Neutralizing interferon-λ2/3 autoantibodies are identified in 11.8% of individuals with cystic fibrosis, >10-fold the prevalence in controls. Autoantibody-containing plasmas enhance respiratory virus replication in vitro and associate with allergic rhinitis in patients, suggesting that interferon-λ2/3 autoantibodies may impact mucosal pathology.

  • Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling

    by Sang-Hun Kim, Jessica Nouws, Jannik Ruwisch, Gavitt A. Woodard, Joseph Cooley, Johad Khoury, Huanxing Sun, Edward Doherty, Marta Piecychna, Edward P. Manning, et al.

    Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.


  • Open Access

    Editorial: The heme oxygenase system in immunity

    by Diego L. Costa, Emanuela M. Bruscia, Dean Willis

    Heme oxygenase (HO) is an enzyme that catalyzes the rate limiting step in the catabolism of heme, which results in the release of equimolar amounts of ferrous iron, the gas carbon monoxide and the bile pigment biliverdin which is subsequently converted to bilirubin by the enzyme biliverdin reductase [1].Two functional isoforms of the enzyme are found in humans, being HO-1 the most studied and well characterized of them. While HO-2 is expressed mainly in testes, gastrointestinal tract and the brain during homeostasis [2], HO-1 expression can be induced in most cells of the human body, usually in response to oxidative but also other types of stresses [3]. HO-1 is highly expressed in spleen and liver macrophages, where it plays a major role in recycling iron from heme contained in hemoglobin molecules released by phagocytosed senescent erythrocytes [4]. The accumulation of heme as well as the activation of macrophages by a number of inflammatory mediators induces the expression of HO-1 in these cells [5]. The enzyme detoxifies heme, which has important toxic oxidant effects in cells, but the products of heme degradation by HO-1 themselves also display potent antioxidant activities and protect cells from damage caused by oxidative stress. In addition to that, the expression and activity of HO-1 promote immunomodulatory effects in macrophages, such as suppression of pro-inflammatory cytokine production [6]. Immunomodulatory activity of HO-1 has also been demonstrated in other leukocyte populations, such as dendritic cells, where the enzyme promotes decrease in antigen presentation capacity and production of pro-inflammatory cytokines [7; 8], and CD4 + T lymphocytes, in which HO-1 promotes immunosuppressive regulatory T cell activities and impairs Th1 and Th17 effector functions [9].Due to its important immunomodulatory properties, the HO-system has attracted considerable attention as a potential therapeutic target by which to treat several pathological conditions be they infectious, inflammatory or neoplastic in nature. This research topic has gathered four articles, including one mini-review and one review, along with two original articles.regulating interactions between endothelial cells and monocytes, with significant implications for transplant vasculopathy (TV) [10]. Transplant vasculopathy remains a major challenge in organ transplantation, primarily driven by donor-specific antibodies that trigger inflammatory responses and vascular injury. This study highlights the importance of HO-1 in attenuating these harmful responses and mitigating TV. Specifically, the authors demonstrate in an in vitro co-culture model that stimulation of endothelial cells with anti-HLA-I antibodies increases monocyte adhesion and transmigration via the adhesion molecule E-selectin (CD62E), which is expressed on cytokine-activated endothelial cells. This process, however, is significantly reduced by pharmacological induction of HO-1. In a murine heterotopic aortic transplantation model, modulation of HO-1 reduced TV, suggesting a protective role against graft inflammation and intimal hyperplasia. Thus, targeting HO-1 provides a novel therapeutic approach to prevent TV and enhance graft survival, offering a promising strategy for improving posttransplant outcomes. Beyond these findings, the study also underscores the broader range of biological mechanisms that rely on the HO-1 pathway to maintain immune responses in check, revealing new avenues for therapeutic intervention [10].High extracellular free heme levels are associated with several pathologies including sickle cell anemia, malaria and sepsis. It is suggested that in these situations free heme causes tissue damage via generating reactive oxygen species, interfering with the functions of lipid membranes and/or acting as a DAMP to activate immune cells.Increased cellular HO-1 expression is believed to be protective against this damage caused by free heme [5]. The paper by Nakagiri et al. reports on the use hemopexin, a heme scavenging protein, as a therapeutic strategy to prevent tissue damage caused by extracellular free heme. Using a mouse pulmonary ischemic-reperfusion model of lung injury, Nakagiri et al. demonstrate that hemopexin administration decreased tissue damage, coagulation and markers of inflammation. Interestingly, hemopexin also decreased HO-1 expression in the ischemic lungs, suggesting that the tissue damaging effect of extracellular heme had been decreased by hemopexin [11]. Being an endogenous high affinity protein, hemopexin has some advantages as a therapeutic e.g. biological starting point, favorable PK/PD and low immunogenicity; however further investigations will need to be carried out to validate its potential, in particular the therapeutic window for hemopexin administration for various pathologies will need to be established. It will also be interesting to see if hemopexin and HO-1 based therapies can be combined.In the review by Yeudall, Upchurch and Leitinger, the authors discuss the role of heme as an important player in the pathogenesis of several inflammatory conditions and the critical role played by HO-1 expression in macrophages as means of attenuating it.More specifically, the authors discuss studies that demonstrate a detrimental role for heme accumulation and release in hemolytic diseases, inflammatory disorders, such as sepsis, and cardiometabolic diseases, such as atherosclerosis, in which heme promotes oxidative stress and inflammatory damage. In such scenarios, HO-1 activity in macrophages plays an important protective effect, by degrading heme, which per se results in reduction of oxidative stress and inflammation, but also by releasing the heme degradation products CO and biliverdin, further converted into bilirubin, which possess potent antioxidant and cytoprotective effects. However, besides in most cases heme is detrimental and HO-1 activity is beneficial, in some infectious diseases as well as...

  • ENaC contributes to macrophage dysfunction in cystic fibrosis

    by John Moran, Courtney Pugh, Nevian Brown, Ashley Thomas, Shuzhong Zhang, Emily McCauley, Amelia Cephas, Chandra L. Shrestha, Santiago Partida-Sanchez, Shasha Bai, et al.

    New research reveals that epithelial sodium channel (ENaC) overexpression in cystic fibrosis (CF) immune cells impairs macrophage function. Inhibiting ENaC increases cystic fibrosis transmembrane conductance regulator (CFTR) expression, normalizes reactive oxygen species production, improves autophagy, and reduces proinflammatory cytokine production. This suggests that ENaC modulation could be a novel therapeutic target for CF infection control, either alone or with CFTR modulators, offering new hope for patients not eligible for current treatments.


  • Prevalence and phenotype of food allergy in children with cystic fibrosis

    by Hang P. Nguyen, Veronika Shabanova, Sarah McCollum, Brooke Polk, Tricia Lee, Kyle Whittington, Priscila Cunha, Emanuela M. Bruscia, Marie E. Egan, Marc Emmenegger, et al.

  • Open Access

    CFTR dictates monocyte adhesion by facilitating integrin clustering but not activation

    by Doulathunnisa Ahamed Younis, Mason Marosvari, Wei Liu, Sunitha Pulikkot, Ziming Cao, Beiyan Zhou, Anthony T. Vella, Sara McArdle, Liang Hu, Yunfeng Chen, et al.

    Monocytes are critical in controlling tissue infections and inflammation. Monocyte dysfunction contributes to the inflammatory pathogenesis of cystic fibrosis (CF) caused by CF transmembrane conductance regulator (CFTR) mutations, making CF a clinically relevant disease model for studying the contribution of monocytes to inflammation. Although CF monocytes exhibited adhesion defects, the precise mechanism is unclear. Herein, superresolution microscopy showed that an integrin clustering but not an integrin activation defect determines the adhesion defect in CFTR-deficient monocytes, challenging the existing paradigm emphasizing an integrin activation defect in CF patient monocytes. We further found that the clustering defect is accompanied by defects in CORO1A membrane recruitment, actin cortex formation, and CORO1A engagement with integrins. Complementing canonical studies of leukocyte adhesion focusing on integrin activation, we highlight the importance of integrin clustering in cell adhesion and report that integrin clustering and activation are distinctly regulated, warranting further investigation for selective targeting in therapeutic strategy design involving leukocyte-dependent inflammation.


  • Open Access

    Ezrin drives adaptation of monocytes to the inflamed lung microenvironment

    by Ravindra Gudneppanavar, Caterina Di Pietro, Hasan H Öz, Ping-Xia Zhang, Ee-Chun Cheng, Pamela H. Huang, Toma Tebaldi, Giulia Biancon, Stephanie Halene, Adam D. Hoppe, et al.

    Ezrin, an actin-binding protein, orchestrates the organization of the cortical cytoskeleton and plasma membrane during cell migration, adhesion, and proliferation. Its role in monocytes/macrophages (MΦs) is less understood. Here, we used a monocyte/MΦ-specific ezrin knock-out mouse model to investigate the contribution of ezrin to monocyte recruitment and adaptation to the lung extracellular matrix (ECM) in response to lipopolysaccharide (LPS). Our study revealed that LPS induces ezrin expression in monocytes/MΦs and is essential for monocytes to adhere to lung ECM, proliferate, and differentiate into tissue-resident interstitial MΦs. Mechanistically, the loss of ezrin in monocytes disrupts activation of focal adhesion kinase and AKT serine-threonine protein kinase signaling, essential for lung-recruited monocytes and monocyte-derived MΦs to adhere to the ECM, proliferate, and survive. In summary, our data show that ezrin plays a role beyond structural cellular support, influencing diverse monocytes/MΦ processes and signaling pathways during inflammation, facilitating their differentiation into tissue-resident macrophages.


  • CCR2+ monocytes are dispensable to resolve acute pulmonary Pseudomonas aeruginosa infections in WT and cystic fibrosis mice

    by Hasan H Öz, Cassia L Braga, Ravindra Gudneppanavar, Caterina Di Pietro, Pamela H Huang, Ping-Xia Zhang, Diane S Krause, Marie E Egan, Thomas S Murray, Emanuela M Bruscia

    Extravasation of CCR2-positive monocytes into tissue and to the site of injury is a fundamental immunological response to infections. Nevertheless, exuberant recruitment and/or activity of these monocytes and monocyte-derived macrophages can propagate tissue damage, especially in chronic inflammatory disease conditions. We have previously shown that inhibiting the recruitment of CCR2-positive monocytes ameliorates lung tissue damage caused by chronic neutrophilic inflammation in cystic fibrosis (CF) mouse models. A potential concern with targeting monocyte recruitment for therapeutic benefit in CF, however, is whether they are essential for eradicating infections such as Pseudomonas aeruginosa (PA), a pathogen that commonly colonizes and damages the lungs of patients with CF. In this study, we investigated the role of CCR2-positive monocytes in the immune response to acute pulmonary PA infection. Our data show that the altered host immune response caused by the lack of monocyte recruitment to the lungs does not impact PA lung colonization, clearance, and the severity of the infection. These results also hold up in a CF mouse background, which have a hyper-inflammatory immune response, yet exhibit reduced bactericidal activity. Thus, we lay the groundwork for future studies to investigate the use of CCR2 inhibitors as a potential therapy to ameliorate lung tissue damage in CF. This could be given alone or as an adjunct therapy with CFTR modulators that significantly improve clinical outcomes for eligible patients, but do not completely resolve the persistent infection and inflammation that drive lung tissue damage.


  • Open Access

    Sputum Induction in Pediatric Lung Disease: Are We There Yet?

    by Tuba Kockar Kizilirmak, Emanuela M Bruscia, Clemente J Britto, Marie E Egan

    Sputum induction (SI) is a non-invasive technique to obtain lower airway samples from people who do not spontaneously produce sputum. Since its introduction in 1958, its use has significantly increased for various respiratory conditions, especially with the establishment of standardized techniques. It has been used in pediatric research since 2002, starting with asthma studies. It is a safe and repeatable procedure for non-expectorating children. The ability to analyze both cellular and fluid components of sputum provides valuable information about lung diseases. This work reviews the utility of sputum induction in pediatric respiratory research and its potential clinical applications. We also discuss the safety, tolerability, and side effects profile of the procedure, emphasizing its significance in pediatric respiratory research. Despite the valuable insights gained from SI studies, challenges remain for widespread clinical utilization, requiring further refinement of the technique and increased accessibility in clinical settings.